Articles related to CME
The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis
Acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity (Ph+) has a poor prognosis historically, so allogeneic hematopoietic cell transplantation (allo-HCT) is advised after the first complete remission (CR1). The rapid achievement of a complete molecular remission (CMR), however, is associated with excellent outcomes without allo-HCT in the tyrosine kinase inhibitor (TKI) era, indicating transplant may not be necessary for these patients. To test this theory, the authors of this journal-based CME program looked into 5 transplant centers in the US to find adult Ph+ ALL patients who received induction therapy, such as TKIs, and received CMR within 90 days of diagnosis. They then compared the outcomes of people who received allo-HCT in the first remission versus those who did not.
Hematology November 28th 2022
Update on Treatment Options for Narcolepsy
After completing this 3-chapter, 0.25-credit CME program, participants should be better able to assess the effectiveness and safety of current and novel therapies in improving outcomes for narcolepsy patients. They should also be able to define the methods by which patients and healthcare professionals can collaborate more effectively to define treatment goals and make decisions that will improve therapeutic outcomes.
Internal Medicine November 8th 2022
Safe Opioid Prescribing: A Patient-Centered Approach to the FDA Blueprint
Part 1—Pain Management Fundamentals Following completion of this activity (1.0 AMA PRA Category 1 Credit™, 1.0 AANP credit, 1.0 ACPE credit, 1.0 ANCC credit), the participant should be able to: Explain the importance of comprehensive pain education Outline the fundamental concepts of pain management, such as pain definitions and pain mechanisms. Examine patients who are in pain, including identifying risk factors for substance abuse and addiction. Discuss the various pain-management approaches, including nonpharmacologic and pharmacologic (non-opioid and opioid analgesic) therapies.
Clinical Pharmacology October 27th 2022
A Persistent Challenge: Managing HIV Multidrug Resistance
After completing this activity, participants will be better equipped to discuss the major difficulties in managing MDR HIV and to illustrate the promise of both existing and forthcoming MDR HIV medicines.
Clinical Pharmacology September 8th 2022
Rebalancing Risk–Benefit With Buprenorphine: An Atypical Opioid Analgesic
1.0 AMA PRA Category 1 Credit™1.0 ACPE contact hour (0.1 CEU) Release Date: May 1, 2022Expiration Date: May 1, 2023 Learning ObjectivesAfter completing this activity, participants should be better able to: Describe the pharmacologic and safety differences between conventional and atypical opioids. Recognize appropriate patients who might benefit from buprenorphine as a first-line opioid analgesic. Understand how to transition opioid therapy from full µ-opioid analgesics to buprenorphine when appropriate.
Clinical Pharmacology August 5th 2022
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
More than 15 professional societies now recommend the use of icosapent ethyl to treat ASCVD, but clinical questions about the use of omega-3 fatty acids remain. Drs. Leslie Cho and Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more in this 13-minute, 0.25-CME credit hours video podcast.
Cardiology August 4th 2022